Dr. John Cush RheumNow
3 years 5 months ago
SAPHYR, presented at #ACR22, unpublished
Robert Spiera at #RNL2023
Phase 3 study for refractory PMR
Sustained remission of disease, less steroids usage, steroid toxicity, and improved PROs
@RheumNow https://t.co/oQJV7gUV3W https://t.co/S1LRBT55Qn
Next-generation DNA sequencing (NGS) techniques show the presence of bacterial DNA in surgical specimens of hip and knee arthritis, from patients undergoing first-time total joint arthroplasty, reports a study in The Journal of Bone & Joint Surgery.
Dr. John Cush RheumNow
3 years 5 months ago
IL-6 for PMR
SPARE and SEMAPORE (Toci), SAPHYR (Sari)
2/2023: FDA approves sarilumab for PMR for inadequate response to corticosteroids or unable to taper off
Robert Spiera @RheumNow #RNL2023 https://t.co/VtzW01Ez7D https://t.co/P6oUQvmDXH
Dr. John Cush RheumNow
3 years 5 months ago
Swedish registry review of #MTX initiation in early #PsA vs #RA (n 3642each). 2 years after MTX start, 71% of PsA vs 76% of patients with RA remained on MTX & the majority (66%/60%) had not started another DMARD, or a biologic (77%/74%) https://t.co/nTJO04sn65 https://t.co/gLjKzj2c74
Dr. John Cush RheumNow
3 years 5 months ago
Evidence-Based Guidelines for EGPA
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, affecting between 10 and 14 cases per million globally.
https://t.co/VixECcPv4R https://t.co/XgEHRgDiPj
Dr. John Cush RheumNow
3 years 5 months ago
RELIEF Trial: Sublingual Cyclobenzaprine in Fibromyalgia
https://t.co/a6KUPcfmxM https://t.co/ToRJQVsZSu
Dr. John Cush RheumNow
3 years 5 months ago
RCT of 122 active plaque Psoriasis pts (38F, 55M) with low vitamin D (~15). Rx w/ either PBO or Vit D (100K IU, followed by 20K IU/wk x 4 mos). Vitamin D supplementation had no effect on psoriasis severity (but pts had mild PSO). https://t.co/JXtEBaop3c https://t.co/ScGtBUIrm0
Dr. John Cush RheumNow
3 years 5 months ago
Subanalysis of the tofacitinib ORAL Surveillance study shows the JAK "at-risk" population are patients Age ≥65 years or ever smoker who exhibited the excess adverse events (malignancies, MACE, MI, VTE, all-cause death) comparedd to TNFi (HRs 1.41–5.19) https://t.co/k78WsPR1Mv https://t.co/JmTDSctIa0
Peresolimab is a humanized IgG1 monoclonal antibody that acts as a programmed cell death protein 1 (PD-1) agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active rheumatoid arthritis (RA).
Dr. John Cush RheumNow
3 years 5 months ago
Juvenile and Adult-onset Scleroderma Differ
A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.
https://t.co/57OrgaUNqj https://t.co/Y2puN18ux0
Dr. John Cush RheumNow
3 years 5 months ago
Black Tongue discoloration in 80 yr old w/ 5 d of fever & shoulder pain, Dx as septic arthritis from Staph. aureus (Rx/ IV cefazolin). Black tongue from Abx? (cephalosporins, PCN, tetracyclines, erythromycins, doxycycline, metronidazole moxifloxacin) https://t.co/lJ91yXOvQ9 https://t.co/mYqwCj3VEL
Dr. John Cush RheumNow
3 years 5 months ago
ICYMI: Our old friend, hydroxychloroquine
https://t.co/NouJayD0T3 https://t.co/lRBl0UQuY3
A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab.
Brepocitinib is a novel tyrosine kinase 2/Janus kinase 1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.
Brepocitinib is an oral, selective Tyk2/JAK1 inhibitor with both immunomodulatory and anti-inflammatory activities and is being studied in dermatomyositis, SLE and PsA.
